N Acetylcysteine B
PreclinicalSmall molecule
N Acetylcysteine B is one of 6 small molecule programs targeting Peritoneal Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Peritoneal Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 1
Paraplatin
AAvyxa
Phase 1
Gemzar
GGynecologic Oncology Group
Phase 1
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 1
Pegylated IFN-Alpha 2b
GGynecologic Oncology Group
Phase 1
N Acetylcysteine B
DDepartment of Medical Services Ministry of Public Health of Thailand
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for N Acetylcysteine B. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details